A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours

This work analysed the influence of the chelating group and radioligand on somatostatin analogues in vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled analogue with similar blood kinetics and biodistribution to 177Lu-DOTATATE and with lower abdominal...

Full description

Saved in:
Bibliographic Details
Published in:Applied radiation and isotopes 2009-02, Vol.67 (2), p.227-233
Main Authors: de Araújo, E.B., Caldeira Filho, J.S., Nagamati, L.T., Muramoto, E., Colturato, M.T., Couto, R.M., Pujatti, P.B., Mengatti, J., Silva, C.P.G.
Format: Article
Language:English
Subjects:
131I
177L
Animals
Chelating Agents
Heterocyclic Compounds, 1-Ring
Iodine Radioisotopes
Lutetium
Mice
Neuroendocrine Tumors - diagnostic imaging
Neuroendocrine Tumors - radiotherapy
Neuroendocrine tumours
Pharmacokinetics
Radioisotopes
Radiolabeling
Radionuclide Imaging
Radiopharmaceuticals - pharmacokinetics
Somatostatin - analogs & derivatives
Somatostatin - pharmacokinetics
Somatostatin analogues
Target therapy
Tissue Distribution
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This work analysed the influence of the chelating group and radioligand on somatostatin analogues in vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled analogue with similar blood kinetics and biodistribution to 177Lu-DOTATATE and with lower abdominal uptake than 131I-TATE. In addition, 131I-DOTATATE showed significative tumour uptake, despite not so persistent after 24 h. 131I-DOTATATE can represent a cost-effective alternative to lutetium labeled peptide for neuroendocrine tumours therapy.
ISSN:0969-8043
1872-9800
DOI:10.1016/j.apradiso.2008.09.009